Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

CJC-1295 with DAC Overview, Dosing & Safety | Peptide Database

CJC-1295 with DAC (CJC-1295 DAC) Long-Acting Growth Hormone Releasing Hormone Analog | Extended Release Community Research Join others researching CJC-1295 with DAC — share findings, ask questions, and learn from real experiences Modified growth hormone releas

By Recovery & Performance Peptides Editorial Team

CJC-1295 with DAC (CJC-1295 DAC)

Long-Acting Growth Hormone Releasing Hormone Analog | Extended Release

Community Research

Join others researching CJC-1295 with DAC — share findings, ask questions, and learn from real experiences

Modified growth hormone releasing hormone engineered for extended duration via albumin-binding technology. DAC binds to albumin, extending half-life and providing continuous GHRH receptor stimulation.

DAC binds to albumin, extending half-life to 6-8 days and providing continuous GHRH receptor stimulation for sustained GH/IGF-1 elevation.

Molecular Data

Tyrosine

Position 1

Alanine

Position 2

Aspartic Acid

Position 3

Position 4

Isoleucine

Position 5

Phenylalanine

Position 6

Threonine

Position 7

Asparagine

Position 8

Serine

Position 9

Position 10

Arginine

Position 11

Lysine

Position 12

Valine

Position 13

Leucine

Position 14

Position 15

Glutamine

Position 16

Position 17

Position 18

Position 19

Position 20

Position 21

Position 22

Position 23

Position 24

Position 25

Position 26

Position 27

Position 28

Position 29

Position 30

Research Indications

Continuous growth hormone release for 6-8 days per injection.

Significantly elevates IGF-1 levels for extended periods.

Weekly dosing ideal for simple administration.

Continuous GH elevation promotes lipolysis and fat metabolism.

Sustained anabolic environment supports muscle protein synthesis.

Accelerated healing and recovery from exercise or injury.

Dosing Protocols

Subcutaneous injection is the preferred route for DAC variant.

Conservative Anti-Aging

1mg

Once weekly

SubQ

Standard Protocol

2mg

Split Dosing

Twice weekly (Mon/Thu)

Loading Protocol

2mg first week, then 1mg

Weekly

Reconstitution Instructions

CJC-1295 with DAC peptide vial

Bacteriostatic water (2-5mL)

Insulin or 1mL syringes

Alcohol prep pads

1 Clean both vial tops with alcohol and dry completely

2 2mg vial: Add 1mL bacteriostatic water (creates 2mg/mL)

3 5mg vial: Add 2.5mL bacteriostatic water (creates 2mg/mL)

4 Inject water slowly to prevent foaming

5 Let sit 5 minutes before gently rolling to mix

6 Solution may appear slightly cloudy initially

7 Label with date and concentration immediately

Interactions

What to Expect

Side Effects & Safety

Common Side Effects

Water retention

Joint pain

Carpal tunnel symptoms

Stop Signs - Discontinue if:

Severe joint pain or carpal tunnel syndrome

Excessive water retention affecting daily life

Numbness or tingling in extremities

Significant blood glucose dysregulation

Signs of acromegaly (jaw growth, hand/feet enlargement)

Persistent lethargy indicating adrenal effects

Contraindications

Diabetes history

Cancer history

Predisposed sleep apnea

Quality Checklist

Good Signs

High purity requirement (>98%); impurities cause more side effects

Proper DAC labeling; legitimate products clearly state 'with DAC'

Warning Signs

Higher cost than non-DAC (2-3x more due to complex manufacturing)

Foaming during mixing is normal for DAC peptides; wait for foam to settle

Bad Signs

Extremely cheap pricing (if priced similar to non-DAC, likely mislabeled)

Clear solution immediately (should be slightly cloudy initially)

Frequently Asked Questions

How much more expensive is CJC-1295 with DAC compared to without DAC?

CJC-1295 with DAC typically costs 2-3x more than the non-DAC version due to complex albumin-binding manufacturing. The higher cost reflects the DAC technology enabling weekly dosing versus daily injections required for the basic version, making weekly administration more convenient despite the price premium.

Is CJC-1295 with DAC safe to combine with testosterone therapy?

CJC-1295 with DAC can be used with testosterone but requires careful monitoring. Combining continuous GH elevation with exogenous testosterone increases risk of joint pain, water retention, and elevated IGF-1 beyond safe levels. Most protocols separate them or use lower doses of each when combined.

Why does some people report joint pain during CJC-1295 DAC use?

Joint pain and carpal tunnel symptoms occur due to sustained GH and IGF-1 elevation causing water retention in joints and connective tissues. Unlike pulsatile protocols where GH spikes then drops, the 6-8 day DAC half-life creates continuous elevation that may stress joints, particularly in high-dose users.

Can you switch between CJC-1295 with DAC and without DAC during a cycle?

Switching between variants mid-cycle is not recommended because they have different pharmacokinetics—DAC provides sustained elevation while non-DAC creates pulsatile release. Combining them risks excessive GH levels and unpredictable effects. Choose one variant at the start and maintain consistency throughout your cycle.

References

Subcutaneous CJC-1295 produced sustained, dose-dependent increases in GH and IGF-1 in healthy adults. Half-life of ~8 days. Cumulative effect after multiple doses with well-preserved GH pulsatility.

Basal (trough) GH levels increased 7.5-fold. Mean GH levels increased 46% and IGF-1 levels increased 45%. Pulsatile GH secretion preserved despite continuous GHRH receptor stimulation.

Identified CJC-1295 as a long-acting GHRH analog through albumin bioconjugation (DAC technology). Binds covalently to endogenous albumin, extending half-life from minutes to days.

Long-acting GHRH stimulation via CJC-1295 produces measurable changes in serum protein profiles reflecting sustained GH/IGF-1 axis activation.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Dosages

Dosages in research are individualized and typically administered via subcutaneous injection. Common protocols include: 100 mcg per injection, 2 times per week. Cycling regimens (e.g., 8-12 weeks on, 4 weeks off) to prevent desensitization. Often dosed at bedtime to align with natural GH pulses. Dosing should be tailored to research goals and subject response, with careful monitoring.
02

Question drills

Open a question for its connected answer.

01What If My Reconstituted CJC-1295 Was Left Out of the Fridge Overnight?+

If the solution was at room temperature (18–25°C) for fewer than 24 hours, refrigerate it immediately and continue use. Short-term ambient exposure causes minimal degradation. Beyond 24 hours or if the temperature exceeded 30°C, discard the vial. Denatured CJC-1295 cannot be visually identified. The solution remains clear even after the peptide structure has collapsed. Using compromised peptide wastes the injection and produces no therapeutic effect. Unreconstituted lyophilised powder tolerates brief temperature excursions better than reconstituted solution, but both should be stored according to protocol without exception.

SOURCE / realpeptides.co ↗
02What If My Reconstituted CJC-1295 Contains Mannitol?+

Verify the concentration. Mannitol is a sugar alcohol used as a stabilizer in some peptide formulations. It's approximately 50% as sweet as glucose and has a glycemic index of 0 in most individuals, meaning it doesn't spike insulin. At the trace concentrations used in peptide reconstitution (typically <1% w/v), mannitol is unlikely to break a fast. If you're using a pre-mixed solution with >5% mannitol by volume, consider switching to a bacteriostatic water-based reconstitution for stricter fasting protocols.

SOURCE / realpeptides.co ↗
03What If the Rodent Data Overestimates Human Response?+

Assume rodent models show 10% lean mass gain but primate models show 4%—what does that mean for human expectations? The answer: expect outcomes closer to primate data. Rodents have higher baseline GH pulse frequency and faster metabolic turnover, amplifying the effect size of any GH-axis intervention. Primates share human-like GH secretion patterns (lower amplitude, higher frequency pulses), making their response curves a better predictor. If you're using cjc-1295 animal research to set realistic goals, the macaque studies—not the rat studies—are the relevant benchmark.

SOURCE / realpeptides.co ↗
04What If I Miss a Scheduled Injection — Should I Double the Next Dose?+

No. Continue with your standard dose at the next scheduled time. CJC-1295's extended half-life means missing one injection reduces weekly IGF-1 area-under-curve by approximately 15–20%, not 50%. Doubling the dose risks receptor saturation (doses above 200mcg show diminishing returns) and may elevate IGF-1 beyond the range that supports muscle recovery without triggering negative feedback. Consistency across weeks matters more than compensating for individual missed doses.

SOURCE / realpeptides.co ↗
05What If I Miss a Scheduled CJC-1295 Injection — Should I Double the Next Dose?+

No. Administer your regular dose (200–300 mcg) as soon as you remember if fewer than 48 hours have passed since your scheduled injection time, then resume your normal twice-weekly schedule. If more than 48 hours have passed, skip the missed dose entirely and wait for your next scheduled injection day. Doubling doses creates supraphysiological GH spikes that trigger somatostatin rebound suppression, which can blunt your response to the following injection and accelerate receptor desensitization. Missing a single dose reduces weekly IGF-1 exposure by approximately 15–20%, but doubling doses to

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

CJC-1295 with DAC vs. CJC-1295 Without DAC: Key Research Differences

A common point of confusion in the research literature involves distinguishing between CJC-1295 with DAC and what is marketed as "CJC-1295 without DAC" (a compound also known as Mod GRF 1-29). These are distinct research chemicals with meaningfully different pharmacokinetic profiles: Half-life ~6 to 8 days ~30 minutes Albumin binding Yes (covalent) No GH pulse pattern Sustained amplitude elevation over days Acute pulse, resolves within hours Administration frequency (research) Once weekly in many protocols Typically multiple times daily DAC linker Present (Lys30 reactive ester) Research use case Chronic GH axis studies Acute GH secretion studies See our article on CJC-1295 without DAC research profile for a detailed comparison and discussion of when each compound is appropriate for different research designs.

RESEARCH

History and Development of CJC-1295 with DAC as a Research Peptide

Research Notice: This article covers the history and scientific development of CJC-1295 with DAC — available from Palmetto Peptides for laboratory use only. Research Use Only Disclaimer: All peptides listed on this page are sold exclusively for in vitro and legitimate laboratory research purposes. They are not intended for human consumption, veterinary use, or any clinical application. The information in this article is for scientific and educational reference only and does not constitute medical advice. All research use must comply with applicable federal, state, and institutional regulations. Palmetto Peptides complies fully with all applicable FDA guidelines. DISCLAIMER: This article is for educational and scientific research reference purposes only. All compounds discussed are not approved by the FDA for use in humans or animals. All data discussed here reflects preclinical animal research or laboratory use. Palmetto Peptides sells these compounds exclusively for in vitro and preclinical laboratory research. Nothing in this article constitutes medical advice. Last Updated: May 18, 2026 | Reading Time: Approximately 13 minutes | Author: Palmetto Peptides Research Team

POTENTIAL BENEFITS

Primary Benefits

Sustained growth hormone increase lasting 6-8 days per injection with clinically documented 2-10 fold elevation Once or twice weekly dosing compared to daily injections required by shorter-acting peptides Enhanced workout recovery and improved sleep quality through sustained IGF-1 elevation
05

Product & matchup locker

Linked catalog and comparison files.

Continue reading

Related articles